FDA Compounding Policy To Have Day In Court In December
This article was originally published in The Pink Sheet Daily
Executive Summary
Ten pharmacies challenging the agency's compounding policy say the lawsuit is an effort to stop "FDA's end-run on the Western States decision," which threw out restrictions on advertising for compounding products.
You may also be interested in...
Compounding Pharmacists Group Asks FDA To Reject Wyeth's Citizen Petition On Premarin
Supporters of Wyeth's petition have financial ties to the company, International Academy of Compounding Pharmacists says.
Compounding Pharmacists Group Asks FDA To Reject Wyeth's Citizen Petition On Premarin
Supporters of Wyeth's petition have financial ties to the company, International Academy of Compounding Pharmacists says.
Compounding Pharmacists Must Use Disclaimer Under Settlement With Chiron
Tobi manufacturer Chiron sued the Respiratory Disease Network over promotion and compounding of tobramycin. Under the settlement, marketing materials for the pharmacy network's product must note that it has not been evaluated by FDA.